The stock of Dexcom Inc (DXCM) has gone down by -1.88% for the week, with a -1.23% drop in the past month and a 18.72% rise in the past quarter. The volatility ratio for the week is 1.05%, and the volatility levels for the past 30 days are 1.47% for DXCM. The simple moving average for the past 20 days is -1.98% for DXCM’s stock, with a 9.76% simple moving average for the past 200 days.
Is It Worth Investing in Dexcom Inc (NASDAQ: DXCM) Right Now?
Dexcom Inc (NASDAQ: DXCM) has a price-to-earnings ratio that is above its average at 63.06x. The stock has a 36-month beta value of 1.46. Opinions on the stock are mixed, with 17 analysts rating it as a “buy,” 6 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for DXCM is 386.47M, and at present, short sellers hold a 2.69% of that float. On June 11, 2025, the average trading volume of DXCM was 4.10M shares.
DXCM) stock’s latest price update
Dexcom Inc (NASDAQ: DXCM) has experienced a decline in its stock price by -0.96 compared to its previous closing price of 84.82. However, the company has seen a fall of -1.88% in its stock price over the last five trading days. businesswire.com reported 2025-06-10 that SAN DIEGO–(BUSINESS WIRE)–Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of DexCom, Inc. (NASDAQ: DXCM) for potential breaches of fiduciary duties and violations of the federal securities laws. What is Johnson Fistel Investigating? Between April 28, 2023 and June 5, 2024, certain DexCom insiders caused the company to issue false and misleading public statements regarding its expansion strategy and purpo.
Analysts’ Opinion of DXCM
Many brokerage firms have already submitted their reports for DXCM stocks, with Goldman repeating the rating for DXCM by listing it as a “Buy.” The predicted price for DXCM in the upcoming period, according to Goldman is $104 based on the research report published on May 30, 2025 of the current year 2025.
Mizuho, on the other hand, stated in their research note that they expect to see DXCM reach a price target of $85. The rating they have provided for DXCM stocks is “Outperform” according to the report published on April 10th, 2025.
Redburn Atlantic gave a rating of “Buy” to DXCM, setting the target price at $115 in the report published on February 03rd of the current year.
DXCM Trading at 8.83% from the 50-Day Moving Average
After a stumble in the market that brought DXCM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -29.29% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at DXCM starting from AUGUSTINOS NICHOLAS, who proposed sale 6,290 shares at the price of $86.91 back on Jun 09 ’25. After this action, AUGUSTINOS NICHOLAS now owns shares of Dexcom Inc, valued at $546,664 using the latest closing price.
Stern Sadie, the EVP, Chief HR Officer of Dexcom Inc, sale 6,184 shares at $85.11 during a trade that took place back on May 27 ’25, which means that Stern Sadie is holding 109,621 shares at $526,318 based on the most recent closing price.
Stock Fundamentals for DXCM
Current profitability levels for the company are sitting at:
- 0.15 for the present operating margin
- 0.59 for the gross margin
The net margin for Dexcom Inc stands at 0.13. The total capital return value is set at 0.17. Equity return is now at value 23.72, with 8.09 for asset returns.
Based on Dexcom Inc (DXCM), the company’s capital structure generated 0.53 points at debt to capital in total, while cash flow to debt ratio is standing at 0.37. The debt to equity ratio resting at 1.14. The interest coverage ratio of the stock is 43.93.
Currently, EBITDA for the company is 945.7 million with net debt to EBITDA at 1.89. When we switch over and look at the enterprise to sales, we see a ratio of 8.32. The receivables turnover for the company is 3.59for trailing twelve months and the total asset turnover is 0.61. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.50.
Conclusion
To sum up, Dexcom Inc (DXCM) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
